<!DOCTYPE html>
<html lang="en">
<head id="Head1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta http-equiv="content-type" content="text/html;charset=utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=Edge" />
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Full Text of HB3472</title>
    <link rel="shortcut icon" type="image/x-icon" href="https://cdn.ilga.gov/assets/img/site/favicon.ico" />
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap.min.css" />
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <script src="https://cdn.ilga.gov/assets/js/fontawesome/fa.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/jquery.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/js.cookie.min.js"></script>
    <script async src="https://cse.google.com/cse.js?cx=a47f92b5e11c1499a"></script> 
    <!-- Bootstrap Datepicker CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap-datepicker.min.css">
    <!-- Bootstrap Datepicker JavaScript -->
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap-datepicker.min.js"></script>
    <!-- aos, bootstrap icons, swiper CSS -->
    <link href="https://cdn.ilga.gov/assets/css/aos/aos.css" rel="stylesheet">
    <link href="https://cdn.ilga.gov/assets/css/swiper/swiper-bundle.min.css" rel="stylesheet">

    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.js"></script>

    <!-- ILGA main CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/main.css" />
    <link rel="stylesheet" type="text/css" media="print" href="https://cdn.ilga.gov/assets/css/print.css">
    <style></style>
    
</head>
<body>
        <!-- ======= Header ======= -->
        <header id="print-header" class="d-flex align-items-center">
            <div class="container-fluid align-items-center text-uppercase justify-content-start ">
                <div class="logo ">
                    <a href="/"><img src="https://cdn.ilga.gov/assets/img/site/white_capitol.png" alt="ILGA Logo"><span>ILGA.GOV</span></a>
                </div>
                <div class="w-100"></div>
            </div>
        </header>
    <input id="TextSearch" type="hidden" />
    <input id="MobileTextSearch" type="hidden" />
    <input id="message-input" type="hidden" />

    <main id="main-content" role="main">
        <section class="main-page p-2">
	<div class="p-1 pt-4 float-left">
		<div class="row border-bottom pb-3 mb-3">
			<div class="text-start">
				<h2>
					HB3472 - 104th General Assembly
				</h2><br />
			</div>
		</div>
		<div id="content">
			<!-- Full text only shows on large screens -->
			<div class="centered-container d-lg-flex">
				<div class="left-aligned-content">
					<div class="row">
						<div class="col pl-lg-5" translate="no">
							<text class="ml-5 text-left fulltextLineHeight" id="billtextanchor">
								<style>
								
								
								
								table.xsl	{ 	border-collapse: collapse;
												border: 0px solid black;
												font-family: "courier New"; 
												font-size: 10pt;}
								
								td.xsl		{ 	border-collapse: collapse;
												border: 0px solid black;
												padding-top: 3pt;
												padding-bottom: 3pt;
												padding-left: 0pt;
												padding-right: 0pt;
												font-family: "courier New"; 
												font-size: 10pt; }
												
								td.junk		{ 	width: 5%; }
								 
							
					
					
						body.xsl		{ 	text-align:center; }
						
					
						td.lineNum 		{ 	vertical-align: top; 
										  	text-align: right;
										  	font-family: "courier New"; 
										  	font-size: 10pt; }
							
						td.number 		{	width: 5%;
											vertical-align: top; 
										  	text-align: right;
										  	font-family: "Courier New", sans-serif;
										  	font-size: 10pt; }
						
						td.synopsis		{ 	border-collapse: collapse;
											border: 0px solid black;
											padding-top: 0pt;
											padding-bottom: 0pt;
											padding-left: 0pt;
											padding-right: 0pt;
											font-family: "courier New"; 
											font-size: 10pt; }
						
						td.rowsep		{ 	border-bottom: 1px solid black; }
											
						td.colsep		{ 	border-right: 1px solid black; }
											
						td.bothsep		{ 	border-right: 1px solid black;
										  	border-bottom: 1px solid black; }
	
						table.top		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black; }
											
						table.bottom	{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-bottom: 1px solid black; }
											
						table.sides		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black; }
	
						table.all		{ 	font-family: "Courier New", sans-serif;
										  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black;
									  	  	border-bottom: 1px solid black;
									  	  	border-top: 1px solid black; }				
	
						table.topbot	{ 	border-collapse: separate;
									  	  	border: outset 0pt;
										  	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black;
									  	  	border-bottom: 1px solid black; }
					
						.sigline		{ 	text-align: left;
							 		 		vertical-align: bottom;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.siglinetext		{ 	text-align: left;
							 		 		vertical-align: top;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.sigtitle		{ 	text-align: left;
							 				vertical-align: top;
							 				padding: 0pt; }
							 				  
						.sigtitlenum		{ 	text-align: right;
							 				vertical-align: top;
							 				padding: 0pt; }
							
						.siglinenum		{ 	text-align: right;
							 				vertical-align: center;
							 				padding-top: 3pt;
							 				padding: 0pt; }
					</style><table class="xsl" width="578"><pre><tr><td class="xsl" colspan="3"><p> </p><br> </td></tr></td></tr><tr><td class="number"></td><td class="junk"></td><td class="xsl"><table class="xsl" width="100%"><tr><td class="xsl"><center><b><pre><font size="3" face="Courier New">104TH GENERAL ASSEMBLY
State of Illinois
2025 and 2026</font><br>HB3472</pre></b></center><p> </p>Introduced 2/18/2025, by Rep. Joyce Mason<p> </p><b>SYNOPSIS AS INTRODUCED:</b><br> </td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><table class="xsl" width="100%"><colgroup width="50%"></colgroup><colgroup width="50%"></colgroup><tr><td class="synopsis"><code>410 ILCS 620/28 new</code></td><td class="synopsis"></td></tr></table><p></p></td></tr><tr><td class="xsl"><code>    </code><code>Amends the Illinois Food, Drug and Cosmetic Act. Provides that any </code><code>health care practitioner authorized by applicable law to issue </code><code>prescriptions for Schedule II controlled substances shall, prior to </code><code>issuing an initial prescription for a Schedule II controlled substance or </code><code>any other opioid pain reliever during a course of treatment for acute or </code><code>chronic pain shall discuss with the patient or the patient's parent or </code><code>guardian, if the patient is under 18 years of age and is not an emancipated </code><code>minor, the risks associated with the drugs being described. Provides that </code><code>the discussion required by this provision shall take place before issuing </code><code>an initial prescription, and again prior to issuing the third prescription </code><code>during a course of treatment. Provides that the prescribing health care </code><code>practitioner shall include a note in the patient's medical record that the </code><code>patient or the patient's parent or guardian, as applicable, has discussed </code><code>with the practitioner the risks of developing a physical or psychological </code><code>dependence on the controlled dangerous substance and on alternative </code><code>treatments that may be available. Provides that these provisions do not </code><code>apply to prescriptions for a patient who is currently in an active </code><code>treatment for cancer, receiving hospice care from a licensed hospice or </code><code>palliative care provider, for a patient who is a resident of a long-term </code><code>care facility, or to any medications being prescribed for use in the </code><code>treatment of substance abuse or opioid dependence.</code></td></tr><tr align="right" class="lineNum"><td class="xsl"><br><br></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left"></td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 10976 RLC 21058 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl"><p> </p><p> </p><center><b>A BILL FOR</b></center><p></p></td></tr></table><p> </p></td></tr><tr><td class="xsl"></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3472</td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 10976 RLC 21058 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>AN ACT concerning health.</code><br> </td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><b><code>Be it enacted by the People of the State of Illinois, </code></b></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><b><code>represented in the General Assembly:</code></b><br> </td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 5. </code><code>The Illinois Food, Drug and Cosmetic Act is </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>amended by adding Section 28 as follows:</code><br> </td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(410 ILCS 620/28 new)</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>Sec. 28. </code></u><u><code>Opioid patients right to know.</code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(a) Any health care practitioner authorized by applicable </code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><u><code>law to issue prescriptions for Schedule II controlled </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><u><code>substances shall, prior to issuing an initial prescription for </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><u><code>a Schedule II controlled substance or any other opioid pain </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><u><code>reliever during a course of treatment for acute or chronic </code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><u><code>pain shall discuss with the patient or the patient's parent or </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><u><code>guardian, if the patient is under 18 years of age and is not an </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><u><code>emancipated minor, the risks associated with the drugs being </code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><u><code>described. The information discussed shall include, but is not </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><u><code>limited to:</code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(1) the risks of addiction and overdose associated </code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" >    <u><code>with opioid drugs and the dangers of taking opioid drugs </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >    <u><code>with alcohol, benzodiazepines, and other central nervous </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <u><code>system depressants;</code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(2) the reasons why the prescription is necessary;</code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(3) any alternative treatments available; and</code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">HB3472</td><td class="xsl" align="center">- 2 -</td><td class="xsl" align="right">LRB104 10976 RLC 21058 b</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><u><code>(4) any additional risks associated with the use of </code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <u><code>the drugs being prescribed, specifically that opioids are </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <u><code>highly addictive, that there is a risk of developing a </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <u><code>physical or psychological dependence on the controlled </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <u><code>substance being prescribed, and that taking more opioids </code></u></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <u><code>than prescribed, or mixing the prescribed medication with </code></u></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" >    <u><code>benzodiazepines, sedatives, or mixing opioids with alcohol </code></u></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <u><code>can result in fatal respiratory depression.</code></u></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(b) The discussion required by subsection (a) shall take </code></u></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><u><code>place before issuing an initial prescription, and again prior </code></u></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><u><code>to issuing the third prescription during a course of </code></u></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><u><code>treatment.</code></u></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(c) The prescribing health care practitioner shall include </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><u><code>a note in the patient's medical record that the patient or the </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><u><code>patient's parent or guardian, as applicable, has discussed </code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><u><code>with the practitioner the risks of developing a physical or </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><u><code>psychological dependence on the controlled dangerous substance </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><u><code>and on alternative treatments that may be available.</code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>(d) This Section does not apply to prescriptions for a </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><u><code>patient who is currently in an active treatment for cancer, </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><u><code>receiving hospice care from a licensed hospice or palliative </code></u></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><u><code>care provider, for a patient who is a resident of a long-term </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><u><code>care facility, or to any medications being prescribed for use </code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><u><code>in the treatment of substance abuse or opioid dependence.</code></u></pre></table>
							</text>
						</div>
					</div>
				</div>
			</div>
		</div>
    </div>
</section>
    </main>
    <!-- Vendor JS Files -->
    <script src="https://cdn.ilga.gov/assets/js/aos/aos.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/popper.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap.bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/glightbox/glightbox.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/swiper/swiper-bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/main.js"></script>

    

</body>
</html>
